肥厚型心肌病的管理:JACC 最新综述
肥厚型心肌病(HCM)是一种常见且常为遗传性的原发性心脏病,现已转变为可治疗疾病。通过成熟的风险分层选择预防性除颤器、手术心肌切除术逆转流出道梗阻所致心衰、抗凝预防房颤相关栓塞等个性化措施,HCM相关死亡率降至0.5%/年。专家小组批判性评估所有数据并提出管理建议。
要点
- 主要标志物可可靠筛选患者植入预防性除颤器,预防心律失常性猝死。
- 手术心肌切除术可逆转流出道梗阻所致进行性心衰,经皮酒精消融为选择性替代。
- 抗凝预防可减少房颤相关栓塞性卒中,消融技术可减少阵发性发作频率。
核心结论
- HCM已转变为高度可治疗的疾病,个性化干预可改变特定不良病程,HCM相关死亡率降至0.5%/年。
研究设计与样本
- JACC最新综述,专家小组批判性评估所有可用数据并提出管理见解和推荐。
主要发现
- 成熟的风险分层中主要标志物可可靠选择患者接受预防性除颤器,预防心律失常性猝死。
- 手术心肌切除术(经皮酒精消融为选择性替代)可逆转流出道梗阻所致进行性心衰。
- 抗凝预防可预防房颤相关栓塞性卒中,消融技术可减少阵发性发作频率。
- 部分患者可接受心脏移植治疗终末期非梗阻性HCM。
- 相当比例HCM患者(主要为无流出道梗阻者)呈稳定/良性病程,无需重大干预。
关键数值与推荐
- HCM相关死亡率降至0.5%/年。
- 当前可用的负性肌力药物姑息性药物治疗可在短期控制部分患者症状,但通常不改变长期临床病程。
临床怎么用
- 对HCM患者应进行成熟风险分层,主要标志物阳性者考虑预防性除颤器。
- 流出道梗阻所致进行性心衰患者可从手术心肌切除术获益,经皮酒精消融为选择性替代。
- 房颤患者应抗凝预防栓塞性卒中,消融技术可减少阵发性发作频率。
- 终末期非梗阻性患者可考虑心脏移植。
- 负性肌力药物可用于短期症状控制,但不应期望改变长期病程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertrophic cardiomyopathy (HCM), a relatively common, globally distributed, and often inherited primary cardiac disease, has now transformed into a contemporary highly treatable condition with effective options that alter natural history along specific personalized adverse pathways at all ages. HCM patients with disease-related complications benefit from: matured risk stratification in which major markers reliably select patients for prophylactic defibrillators and prevention of arrhythmic sudden death; low risk to high benefit surgical myectomy (with percutaneous alcohol ablation a selective alternative) that reverses progressive heart failure caused by outflow obstruction; anticoagulation prophylaxis that prevents atrial fibrillation-related embolic stroke and ablation techniques that decrease the frequency of paroxysmal episodes; and occasionally, heart transplant for end-stage nonobstructive patients. Those innovations have substantially improved outcomes by significantly reducing morbidity and HCM-related mortality to 0.5%/y. Palliative pharmacological strategies with currently available negative inotropic drugs can control symptoms over the short-term in some patients, but generally do not alter long-term clinical course. Notably, a substantial proportion of HCM patients (largely those identified without outflow obstruction) experience a stable/benign course without major interventions. The expert panel has critically appraised all available data and presented management insights and recommendations with concise principles for clinical decision-making.
引用
- Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022. PMID: 35086661. doi:10.1016/j.jacc.2021.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。